CD4 and neoplasm: Notably, context matters: in human NSCLC, apCAFs have been observed adjacent to—and capable of activating—CD4+ T cells, suggesting that even within the “apCAF” label, function can range from tolerogenic (Treg-inducing) to immunostimulatory, depending on tumor type and microenvironment.